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Fibroblast growth factors are key proteins inmany intercellular
signalingnetworks.Theynormallyremainattachedtotheextracel-
lular matrix, which confers on them a considerable stability. The
unrestrained accumulation of fibroblast growth factors in the
extracellular milieu, either due to uncontrolled synthesis or enzy-
matic release, contributes to the pathology ofmany diseases. Con-
sequently, the neutralization of improperly mobilized fibroblast
growth factors is of clear therapeutic interest. In pursuing
described rules to identify potential inhibitors of these proteins,
gentisic acid, a plant pest-controlling compound, an aspirin and
vegetarian diet common catabolite, and a component ofmany tra-
ditional liquors and herbal remedies, was singled out as a powerful
inhibitor of fibroblast growth factors. Gentisic acid was used as a
lead to identify additional compoundswith better inhibitory char-
acteristics generatinganewchemical classof fibroblast growth fac-
tor inhibitors that includes the agent responsible for alkaptonuria.
Through lowandhigh resolution approaches, using representative
membersof the fibroblastgrowth factor familyandtheir cell recep-
tors, it was shown that this class of inhibitors may employ two dif-
ferent mechanisms to interfere with the assembly of the signaling
complexes that trigger fibroblast growth factor-driven mitogene-
sis. In addition, we obtained evidence from in vivo disease models
that this group of inhibitors may be of interest to treat cancer and
angiogenesis-dependent diseases.
The fibroblast growth factors (FGFs)4 constitute one of the
largest families of polypeptide growth factors. There are 22
FGFs in humans and mice that differ significantly in both size
(17–20 kDa) and sequence, although each contains a core
homology region encompassing 120–130 residues. Phyloge-
netic analyses suggest that the FGF genes can be arranged into
seven subfamilies. All FGFs bind to heparin with high affinity
(Kd between 1–2 nM), except for the members of the FGF-19
subfamily (i.e.: FGF-15, -19, -21, and -23) that have little or no
affinity for these glycosaminoglycans (1). Apart from the family
comprising FGF-11 to FGF-14, FGFs exert their diverse biolog-
ical actions by binding to a series of membrane tyrosine kinase
receptors (FGFRs) that are encoded by four genes (2–4). For
this reason the FGF family is currently considered to be consti-
tuted by 18 members.
FGFs were first isolated in the 1980s from bovine brain
extracts due to their mitogenic and angiogenic activities (5).
The affinity of FGFs for heparin was recognized very soon after
their discovery (6), although the physiological substrate for FGF
in normal conditions is heparan sulfate, a proteoglycan whose
glycosidemoiety is a glycosaminoglycan like heparin. Although
initially conceived as FGF traps and protectors, it was later
shown that these proteoglycans also participate in FGF signal-
ing, although they are not absolutely required (4, 7, 8).
In addition to the effects on cell replication and angiogenesis
observed initially, FGFs regulate cell survival, apoptosis, prolif-
eration, differentiation, matrix composition, chemotaxis, cell
adhesion, and migration. Different cell types or even the same
cellmay display alternate and sometimes opposing responses to
FGFs, depending on their state of differentiation, biochemical
status, or the cellular, physical and chemical environment of the
cell (4). These activities govern a wide variety of developmental
and physiological processes, as practically all cell lineages
derived from the embryonicmesoderm and neuroectoderm are
under the control of these proteins. At the same time FGFs have
been detected in most adult tissues derived from these embry-
onic cell types under physiological conditions. FGFs, at times
expressed at very high levels, normally remains trapped in the
* This work was supported by BFU2008-02595 from theMinisterio de Educa-
cio´n y Ciencia (Spain).
□S The on-line version of this article (available at http://www.jbc.org) contains
supplemental Figs. S1–S4.
The atomic coordinates and structure factors (codes 3JUT and 3K1X) have been
deposited in the Protein Data Bank, Research Collaboratory for Structural
Bioinformatics, Rutgers University, NewBrunswick, NJ (http://www.rcsb.org/).
1 Recipient of a Ph.D. fellowship from the Ministerio de Educacio´n y Ciencia
(Spain).
2 Sponsored by a fellowship of the Fundacio´n Futuro (Spain).
3 Towhomcorrespondence should be addressed: Ramiro deMaeztu 9, 28040
Madrid, Spain. E-mail: gimenez_gallego@cib.csic.es.
4 The abbreviations used are: FGF, fibroblast growth factor; FGFR, plasmale-
mmal tyrosine kinase FGF receptor; 2,5DHPS, 2,5-dihydroxyphenylsulfon-
ate; 5A2NMS, 5-aminonaphthalene-2-sulfonic acid; exdFGFR2IIIc, com-
plete extracellular domain of the IIIc isoform of FGFR2; I50, half-maximum
inhibitory activity; IDS-3, O2-sulfoglucuronic acid; GA, gentisic acid (2,5-
dihydroxybenzoic acid); HGA, homogentisic acid (2-(2,5-dihydroxyphenyl)
acetic acid); SGN-4, N,O6-disulfoglucosamine; STD, saturation transfer dif-
ference NMR spectroscopy; HSQC, heteronuclear single quantum correla-
tion; VEGF, endothelial cell growth factor.
THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 285, NO. 15, pp. 11714–11729, April 9, 2010
© 2010 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in the U.S.A.
11714 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 285•NUMBER 15•APRIL 9, 2010
 at CSIC - Centro de Investigaciones Biológicas on Septem
ber 22, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
 at CSIC - Centro de Investigaciones Biológicas on Septem
ber 22, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
 at CSIC - Centro de Investigaciones Biológicas on Septem
ber 22, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
 at CSIC - Centro de Investigaciones Biológicas on Septem
ber 22, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
 at CSIC - Centro de Investigaciones Biológicas on Septem
ber 22, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
 at CSIC - Centro de Investigaciones Biológicas on Septem
ber 22, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
extracellular matrix, from which they are released by hepara-
nases or other specialized proteins when necessary (9–16).
Obviously, the subversion of this powerful signaling system and
any defects in its tight control, either through uncontrolled syn-
thesis or the continuous mobilization of matrix bound FGFs,
may cause very serious physiological disturbances (17). Indeed,
it was recently shown that mutations in FGFs that decrease
their affinity for heparan sulfate in the extracellular matrix and,
consequently, that increase their diffusion through developing
tissues led to the ectopic signaling responsible for the mouse
Elbow knee synostosis syndrome (18).
Over the last 20 years, a wealth of information has accumu-
lated regarding the involvement of different members of the
FGF family in pathological conditions, much of which is related
to cancer. Elevated levels of FGFs are detected in the serum of
cancer patients (19). Sometimes FGFs seem to be directly
involved in tumorigenesis by the autocrine, paracrine of juxta-
crine induction of the growth of the cancer cells. In addition,
FGF signaling may affect processes other than growth associ-
ated to tumor progression. For example, they can be involved in
the creation of profuse blood irrigation networks to sustain the
intense metabolism of the tumor cells, which subsequently
favor their dissemination throughout the organism. Tumor
metastasis is additionally favored by the activation of enzymes
that degrade the basement membrane and the enhancement of
cell motility by FGFs.Moreover, they are also involved in inhib-
iting apoptosis, enhancing the survival of tumor cells, promot-
ing the resistance of tumors to chemotherapeutic drugs and
radiation, controlling tumor dormancy (a step in tumor pro-
gression), and controlling the self-renewal of cancer stem cells.
FGFs may also participate in paraneoplastic events in cancer
patients (20–25).
Based on a relativelywide screening of naphthalene sulfonate
derivatives and on three-dimensional structural studies, we
recently presented a set of chemical leads to develop FGF inhib-
itors. The most promising inhibitor of this family of com-
pounds was 5-aminonaphthalene-2-sulfonic acid (5A2NMS).
These studies led us to propose some rules that can be applied
to search for newFGF inhibitors (26).On the basis of these rules
we have since searched for further potential candidates to
inhibit FGFs, examining different libraries of natural products.
We found that gentisic acid (GA; 2,5-dihydroxybenzoic acid), a
widespread plant secondarymetabolite involved in pest defense
and a catabolite of aspirin, is a potential inhibitor of FGF (27–
32). Here we show that GA does indeed define a new chemical
group of FGF inhibitors, which includes homogentisic acid
(HGA; 2-(2,5-dihydroxyphenyl)acetic acid), the toxic agent in
alkaptonuria. Indeed, these compounds inhibit relevant activi-
ties attributed to the two prototypical members of the family in
vitro and in vivo. The chemical constraints that define the effi-
ciency of these aromatic derivatives in inhibiting FGF are also
identified; the para conformation of the dihydroxyphenyl
group and the functionalization of the aromatic ring by an
acidic group. We also show that these compounds recognize
both the growth factors and their receptors, displacing hep-
arin from its binding site in these polypeptides, change the
three-dimensional structure of the growth factor at their
receptor recognizing site, and are capable of dissociating the
receptorgrowth factor signaling complex.
EXPERIMENTAL PROCEDURES
Protein Expression Purification and Analysis—The cDNAs
encoding FGF-1 and FGF-2 were cloned into the pRAT-4 plas-
mid, expressed in Escherichia coli BL21(DE3), and purified by
heparin-Sepharose chromatography (33, 34). The protocol to
uniformly labeled 15N synthesis has already been described
(35). C-LYT/aFGF was produced and purified by heparin-
Sepharose chromatography as described previously (36). To
express the extracellular domain (residues 25–361) of receptor
2 IIIc isoform (exdFGFR2IIIc), an expression cassette was con-
structed by PCRusing pTK14 as the template (37) and using the
nucleotide modifications proposed by ProteoExpert (Biomax
Informatics AG) for optimal expression of the protein in E. coli.
The cassette includes the T7 promoter of phage RNA polymer-
ase, exdFGFR2IIIc with a His tag fused to its C terminus and
optimized for Ni2-chelating chromatography, and a 3-un-
translated region optimized for protein expression in which a
T7 phage RNA polymerase terminator has been included
(supplemental Fig. S1). The cassettewas inserted into the 5 end
of the SmaI site of pUC19 vector by blunt end ligation to gen-
erate the expression plasmid pUCexdFGFR2IIIc. The E. coli
BL21(DE3) strain C41 was used for expression (14). To synthe-
size exdFGFR2IIIc, 1 liter of LBmediumwas inoculatedwith an
overnight culture of the transfected cells grown to an A660 of
0.05 and incubated with shaking at 37 °C. When the culture
reached an A660 of around 0.7, protein expression was induced
with isopropyl--D-thiogalactoside (1 mM). Five hours later the
cells were harvested by centrifugation, resuspended in 50 mM
Tris-HCl (pH 8), 0.5 M KCl, and 5 mM EDTA and lysed by
sonication. The insoluble material was recovered by centrifu-
gation (15,000 g), and it was resuspended in wash buffer (50
mM Tris-HCl (pH 8.0), 2 mM dithiothreitol, 0.5 M KCl, 1% Tri-
ton X-100, 0.5% sodium deoxycholate, 0.5% Sulfobetaine-12)
before recovering the insoluble material by centrifugation as
above. The insolublematerial recovered was dissolved in buffer
(50 mM Tris-HCl (pH 8.0), 2 mM dithiothreitol, 5 M guani-
diniumHCl), loaded onto a 20-mlNi2-chelating column (His-
TrapFF HP, GE Healthcare), and subjected to chromatography
using a 0–0.5 M gradient of imidazole in 20 column volumes of
the same buffer. The material eluted almost exclusively as a
single peak that corresponded to pure exdFGFR2IIIc on SDS-
PAGE analysis. A yield of 100 mg of protein per liter of culture
was estimated at this stage. The purified exdFGFR2IIIc was
diluted to an A280 of 0.24 in 50 mM Tris-HCl (pH 8.0), 2 mM
dithiothreitol, and 5 M guanidinium HCl, and it was stored at
80 °C in 30-ml aliquots. For protein refolding, an aliquot (30
ml) was dialyzed against a linearly increasing volume (70–5000
ml, 17 h, 277 K) of 20mMHepes (pH 7.5), 150mMNaCl, and 0.1
mM reduced and 1 mM oxidized glutathione. In this way the
guanidine levels decreased slowly at the critical concentrations
so that the protein could reshuffle and find its native conforma-
tion. The dialysis process was repeated a second time using the
same buffer except that the glutathionewas omitted. At the end
of the whole process the guanidine concentration was1 mM,
and protein recovery after the refolding process was consis-
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tently 90%. A¨KTAprime and A¨KTAdesign chromatogra-
phers (GE Healthcare) were used for protein purification and
analysis, respectively.
Proliferation Assays—The assays to test the inhibition of
FGF-driven mitogenesis using murine Balb/c 3T3 fibroblasts
have already been described (26). The FGF-1 andmyo-inositol
hexasulfate concentrations were 0.64 ng/ml and 100 g/ml,
respectively. When FGF-2 was tested, 1 ng of the growth factor
and 10 g of heparin per ml were used. Cells were counted by
measuring the total amount of crystal violet fixed by cell nuclei
by differential absorbance (38). The mitogenesis assays with
FR1c-11 cells (kindly provided by D. M. Ornitz, Washington
University) have been described previously, except that a single
FGF-1 concentration was used (160 ng/ml) in the experiments
reported here, and the cells were pretreated before the assay by
overnight incubation in the culture conditions at 220,000 cell/
ml, as detailed under “Results” (7). Just before the assay, the
pretreated cells were diluted 10-fold with culture medium
(without interleukin-3), theywere packed by centrifugation to a
volume of 50 l, and they were again suspended in 10 ml of
the same medium. After repeating the last washing step three
times, the suspension was brought to a final concentration of
220,000 cells/ml. The cell number was determined at the end of
the assay by monitoring the reduction of 2,3-bis[2-methoxy-4-
nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxanilide (XTT;
Roche Applied Science, cell proliferation kit II) by differential
absorbance. All the mitogenesis assays were carried in quadru-
plicate. Deviation bars represent the S.E.
Migration Assay—Inhibition of FGF-induced Balb/c 3T3
fibroblast migration in culture was tested as described previ-
ously (39). Briefly, fibroblasts cultured in Dulbecco’s modified
Eagle’s medium supplemented with 10% heat-inactivated calf
serum, 2 mM L-glutamine, 103 units of penicillin/ml and 12
mg/ml gentamicinwere seeded in the samemediumat a density
of 25  103 cells onto glass coverslips covering the bottom of
24-well culture plates. Once the cells reached confluence, a lin-
ear wound across the diameter of the coverslip was drawn with
a rubber cell scrapper, and the medium was changed to Ham’s
F-12/Dulbecco’s modified Eagle’s medium (1:3) supplemented
with a 1/100 (v/v) dilution of culture supplement ITS (Col-
laborative Research), 2.5 mM L-histidine, 2 mM L-glutamine, 50
mM ethanolamine, 0.1 mg/ml myo-inositol hexasulfate, 103
units/ml penicillin, 12mg/ml gentamicin, and the doses of FGF
and inhibitor detailed under “Results.” The cultures were fixed
48 h afterward in a 1% solution of glutaraldehyde, and theywere
stainedwith crystal violet as described (36). Each treatmentwas
tested in three different cultures, and the total number of
migrating cells in the entire wound was determined by manual
counting under a light microscope. Only cells with a migratory
phenotype were considered.
Angiogenesis Assays—Sterile gelatin sponges (1 cm3;
CurasponDental,ClinimedHolding,Zwanenburg,TheNether-
lands) were implanted subcutaneously into the dorsal region of
the neck in 10 intraperitoneally anesthetized Sprague-Dawley
rats. The sponges were moistened with 200 l of phosphate-
buffered saline containing 25 g/ml heparin and 10 g/ml
FGF-1. After implanting the sponges, the rats were randomly
assigned to groups (n  5) that received treatment by gavage
with either the inhibitor (150 mg/kg twice daily) or the vehicle
alone (tap water). After 7 days, the sponges were removed, pho-
tographed, fixed by immersion in 4% paraformaldehyde,
embedded in paraffin, sliced in 6-msections, and stained with
hematoxylin-eosin. The number of functional blood vessels
(those containing erythrocytes) in six random fields (0.176
mm2) per sponge was determined by morphometric analysis
(Motic Images Advanced 3.0, Xiamen, China) and averaged.
Progression of Subcutaneously Implanted Rat Gliomas—Rat
C6 glioma cells were cultured as described previously (40). C6
cells cultured to confluence in 75-cm2 flasks were removed
and implanted under the abdominal skin (5 105 cells in 10
l of culture medium) of anesthetized rats according to the
procedures described previously (41). Those rats that devel-
oped a tumor in the same area 5 days after implantation of
the tumor cells were randomly assigned for daily intraperi-
toneal injections (300 l) of either the inhibitor (100 mg per
kg of animal; n  6) or the vehicle alone (0.9% NaCl; n  6).
After 10 days of treatment, the subcutaneous gliomas were
removed, and their volume was calculated according to the
formula V 4/3(L/2)(A/2)2, where L is the larger diameter,
and A is the smaller diameter, both expressed in mm.
Crystallization, Data Collection, Structure Determination,
and Refinement—Crystals of the complex between FGF-1 and
the inhibitors were grown using the sitting drop vapor diffusion
method at 295K. Equal volumes of protein (0.75mM) and inhib-
itor (1.5 mM) solutions were mixed with drops containing 60%
sodium/potassium tartrate buffered with 5 mM sodium phos-
phate (pH 7.8). The drops were equilibrated against 200 l of
1.3 M Li2SO4, and typically the crystals grew to0.7 0.5 0.2
mm within 2 weeks.
For the diffraction experiments, the crystals were flash-fro-
zen in liquid N2 after transfer to a cryoprotectant buffer: 20%
(v/v) glycerol and 60% sodium/potassium tartrate bufferedwith
5 mM sodium phosphate (pH 7.8). Complete data sets were
collected on CCD detectors at 100 K at the European Synchro-
tron Radiation Facility (Grenoble), beamline BM14. The dif-
fraction images were processed with MOSFLM (42) and scaled
with the CCP4 suite (43). The crystals belong to themonoclinic
system with space group P2. The structure was solved by
molecular replacementwith theAMoRe software (44) using the
coordinates of the native FGF-1 (PDB code 1axm) as a search
model (45). Using this method, the position of six protein mol-
ecules could be located by molecular replacement searches.
With six protein molecules in the asymmetric unit, the Mat-
thews coefficient was calculated to be 2.4 Å3 Da1, and the
solvent content was 48.0% (46). Electron density visualization
and model building were carried out with COOT (47). After
rigid-body and simulated-annealing torsion-angle refinement,
the position of the inhibitors was clearly defined at the heparin
binding site from the electron density maps. Furthermore,
inspection of the initial sigma-A maps showed that a few
regions were disordered, although some electron density was
obvious. This problemwas overcome by the use of non-crystal-
lographic symmetry restraints that were then removed in the
final refinement steps. The topology and parameter values for
the 2,5-dihydroxyphenylsulfonate (2,5DHPS) and GA ligands
were generated using the Dundee PRODRG2 server (48). Sev-
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eral rounds of simulated annealing and B factor refinement
withCNSwere combinedwithmodel rebuilding inCOOTafter
inspection of both the 2Fo  Fc and Fo  Fc maps (49). The
coordinates for the final model have been deposited at the Pro-
tein Data Bank under the codes 3JUT and 3K1X for FGF-1
bound to GS and 2,5DHPS, respectively.
Nuclear Magnetic Resonance Spectroscopy—Two-dimen-
sional 1H,15NHSQC spectra were acquired at 298 K in a Bruker
AVANCE 500 MHz spectrometer. The number of acquired
complex points were 1024 in t2 (1H) and 128 in t1 (15N) with
spectral widths of 6009.61 (12 ppm) and 2534.18 (50 ppm),
respectively.
Saturation transfer difference (STD) experiments were car-
ried out using the same equipment. The spectra were acquired
at 298 K with 4096 scans, and selective protein saturation was
achieved with a train of 40 Gauss-shaped pulses of 50 ms and a
delay between pulses of 1 ms. The on-resonance irradiation of
the protein was performed at 0 ppm, and the off-resonance
irradiation was set at 50 ppm. Both on- and off-resonance spec-
tra were subtracted through phase cycling. As a control, a STD
experiment was carried out in which exdFGFR2IIIc was omit-
ted from the solution.
RESULTS
The potential inhibition of FGFmitogenic activity byGAwas
first assayed in vitrousing FGF-1 andBalb/c 3T3 fibroblasts (26,
38), where it displayed a half-maximum inhibitory activity (I50)
of 36 M (Fig. 1A). This value was considerably lower than
that reported for other inhibitors we have used as lead com-
pounds (26, 38), the best of which was 5A2NMS with an I50 of
265 M. In the absence of FGF, the number of quiescent cells
did not vary at the concentrations of GA tested (Fig. 1A, open
triangle). Hence, the decrease in cell number observed in the
cultures challenged with FGF-1 did not seem to be due to the
survival of the cells but, rather, to a decrease in the specific
activity of the mitogen.
The full set of GA isomers is commercially available, and
thus, we carried out a systematic exploration of the effects of
the different relative positions of the two hydroxyls on the inhi-
bition of FGF-1 mitogenic activity. Surprisingly, we found that
the entire set of isomers tested was inactive at concentrations
three times the I50 of GA. Neither inhibition nor toxicity
was evident at the GA isomer concentrations tested
(supplemental Fig. S2). Acetylsalicylic acid, a precursor of GA
in animals (32), was also inactive at concentrations up to 1 mM.
We also studied the effect of substituting the acidic group of
GA. The effect of the substitution of the carboxylic group by an
amino group could not be tested because the resulting com-
pound was too unstable to use in these mitogenic assays. The
elimination of the acidic group converts GA to hydroquinone, a
compoundwithwell documented toxicity that strongly reduces
cell viability in these assays at low micromolar concentrations.
Consequently, we could only test the substitution of the car-
boxylate group with other functional acidic groups. Substitu-
FIGURE 1. Inhibition of the FGF-driven mitogenesis in cultures of Balb/c
3T3 fibroblasts by 2,5- dihydroxyphenyl acids. A, GA. B and D, 2,5DHPS.
C, HGA. A–C, FGF-1. D, FGF-2. AU, absorbance units.
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tion of carboxylate by phosphonate caused a consistent but not
dramatic decrease in the I50 (typically 24 M). Nevertheless, a
considerable decrease in the I50 of approximately 1 order of
magnitude (3 M versus 36 M) was observed when this group
was replaced by sulfonate (2,5DHPS, Fig. 1B). HGA is an inter-
mediate compound in tyrosine catabolism that reaches abnor-
mally high levels in people affected by the recessive genetic
disease known as alkaptonuria. In this compound an acetate
group substitutes the carboxylate of GA. HGA inhibits FGF-1
with an I50 of 6.8 M (Fig. 1C), similar to the activity of
2,5DHPS.With both compounds, the number of quiescent cells
also remained relatively constant at the concentrations of
inhibitor tested (Fig. 1, open symbols).
Atomic Structure of FGF-1 Bound to 2,5DHPS and GA—In-
hibition of the mitogenic activity of FGF by 2,5-dihydroxyphe-
nylic acids seems to be exquisitely tuned. To gain insight into
the molecular basis of this interaction, FGF-1 was crystallized
in the presence of two of these inhibitors, the least active GA
and themost active 2,5DHPS. The structure of these complexes
was then solved by x-ray diffraction analysis.
Monoclinic crystals of the complex between FGF-1 and these
inhibitors were obtained in solutions containing sodium potas-
sium tartrate as themain precipitant, which reached theirmax-
imum size in about 2 weeks. These crystals belong to the P2
space group, containing six molecules in the asymmetric unit,
and they diffracted up to 2.0 Å under synchrotron radiation.
The structures were solved by molecular replacement as
described under “Experimental Procedures.” In the final
models, the majority of the residues were located in the most
favored regions of the Ramachandran plot. The data collec-
tion, structure determination, and refinement statistics are
summarized in Table 1. As already observed for the
5A2NMS/FGF-1 structure (26), GA and 2,5DHPS were not
detected in four of the six molecules of the asymmetric unit,
probably due to steric clashes from the neighboring symmet-
rically related molecules. In the other two molecules a very
clear electron density of about 2 was observed, into which
2,5DHPS and GA could easily be modeled. After the final
refinement both inhibitors and the neighboring protein res-
idues were clearly defined and oriented in the 2Fo Fc elec-
tron density maps (Fig. 2, top row).
Inhibitor Binding Site—Both 2,5DHPS and GA bind in a 1:1
stoichiometric ratio to a positively charged cavity at the surface
of FGF-1, part of the long cationic channel that constitutes the
FGF-1 heparin binding site (Fig. 2,middle row) (45). The figure
clearly suggests that strong steric hindrances prevent the simul-
taneous binding of more than one ligand to FGF-1. GA and
2,5DHPS dock at adjacent sites within a small groove that is
partially occupied by the N of Lys-132 and that is formed by
residues belonging to the  strand 10 and the loops between 
strands 1 and 2 and strands 11 and 12 (Fig. 2, bottom row) (50).
Two sulfate groups dwell in this pocket that somehow grasps
Lys-132 in the reported crystallographic structure of the FGF-
1heparin complex, those belonging to O2-sulfoglucuronic acid
at position 3 (from the reducing end; IDS-3) and the amino
group of N,O-6-disulfoglucosamine at position 4 (SGN-4)
(illustrated in supplement Fig. S3) (45, 51). This groove is highly
conserved between FGF-1 and FGF-2 (at the primary structure
level there is only one conservative substitution in eight resi-
dues: Lys-127 for Arg-129), and when the two proteins were
crystallized in the absence of heparin, the position of the IDS-3
sulfate is occupied by strong anions like phosphate or selenate
(illustrated in the supplement Fig. S4) (52–54). Lys-132 seems
to be very important to create the specific physicochemical
conditions at this groove that are critical for both heparin affin-
ity and mitogenic activity of FGF-1. Indeed, these characteris-
tics are strongly diminished when Lys-132 is either methylated
or substituted by a non-cationic residue (8, 55). The aromatic
ring of 2,5DHPS occupies an intermediate position between the
binding sites for the two heparin sulfates that surround Lys-
132, whereas that of GA is approximately situated at the posi-
tion of the sulfate of SGN-4 (Fig. 2, bottom row).
The binding of GA and 2,5DHPS causes specific rear-
rangements of the side chains of the residues at the binding
site that do not affect to their amide backbone (Fig. 2, bottom
row, and Fig. 3, top row, left). It should be noted that when
the amide backbones of FGF-1 bound to 2,5DHPS and GA
are superimposed, they match closely (Fig. 3, middle row,
left). Furthermore, as shown in the same figure, a similar
close match was observed when the backbone of FGF-1
bound to 5A2NMS was superimposed on those of the pro-
tein bound to the two former inhibitors. This result was
unexpected, because although 5A2NMS binds to the same
site than 2,5DHPS and GA, it is a compound chemically
unrelated to them, and it docks in a totally different fashion
(26).
Both 2,5DHPS and GA appear stabilized at their binding site
by a network of non-covalent contacts. In the case of 2,5DHPS,
the aromatic ring establishes a canonical -cation interaction
with the N of Lys-132 (56); the negatively charged sulfonate
group establishes a salt bridge with the N of Lys-127; the
TABLE 1
Data collection and refinement statistics
ASU, asymmetric unit.
FGF-1/2,5DHPS FGF-1/GA
Data collection statistics
Space group P2 P2
Cell dimensions (Å, °)
a 97.0 a 97.7
b 47.3  106.7 b 47.7  106.4
c 97.9 c 98.4
No. molecules in ASU 6 6
Wavelength 0.979 0.979
Resolution (Å)a 30.01-2.0 (2.13-2.00) 47.78-2.20 (2.33-2.20)
Measurements 615,365 324,202
Unique reflections 63,239 42,342
Rmerge (%)a 5.9 (42.8) 8.2 (32.8)
I/(I)a 8.2 (2.5) 11.2 (4.5)
Completenessa 98.4 (88.6) 95.4 (94.6)
Refinement statistics
Resolution range (Å) 30.01-2.00 37.01-2.20
Reflections (work/free) 57,645/5,594 36,289/1,910
Rwork/Rfree (%) 22.7/27.31 21.88/27.40
Root mean square deviation
Bond lengths 0.021 0.026
Bond angles 1.88 2.01
No. atoms 6,366 6,272
Protein 6,226 6,226
Ligand 24 22
Solvent 116 24
Average B factor (Å2) 46.84 38.52
Ramachandran analysis; favored
regions/allowed regions/
outliers (% of residues)
93/6/1 94/5/1
a Values are for the last resolution shell.
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hydroxyl group at position 2 establishes two simultaneous
directional hydrogen bonds with the N of Lys-142 and the N
of Ala-143, respectively (Fig. 3, bottom row, left). GA occupies a
position with different coordinates despite its similarity with
2,5DHPS and although it docks at the same FGF-1 cleft as
2,5DHPS. There, its hydroxyl group at position 5 establishes
FIGURE 2. Binding of GA and 2,5DHPS to FGF-1. Top row, stereo diagrams of the 2,5DHPS (left) and GA (right) FGF-1 binding sites show the electron density
maps for the inhibitors and their adjacent side chains. Electron densities, corresponding to the final 2Fo Fcmaps are shownat the 1 contour level.Molecular
models of the side chains and the inhibitors are represented by solid sticks (white, carbon; red, oxygen; blue, nitrogen), and the protein backbone is shown as
a transparent gray schematic. The figure was produced using the PyMOL program (DeLano Scientific LLC).Middle row, shown are molecular surface represen-
tations of FGF-1 complexed with heparin (A) (45), GA (B), and 2,5DHPS (C). The ligands are shown as solid sticks colored as above. The electrostatic potential of
the protein surfacemapped in blue (positive) and red (negative) was generated using the same parameters in each of three cases with the APBS program (89).
Bottom row, shown are stereoviews of the three-dimensional structure of the FGF-1 binding site for 2,5DHPS (left) and GA (right). Both inhibitors, shown as
stick-and-ballmodels (gray, carbon; red, oxygen; yellow, sulfur) appear inside the semitransparent representation of their van der Waals volume. The electro-
static potential of the protein surface is mapped in blue (positive) and red (negative), and it was generated with the Discovery Studio Visualizer program
(2.0.1.7347; Accelrys Software Inc.) using its internal parameters to calculate the electrostatic potential.
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simultaneous hydrogen bonds with the N2 of Asn-32 and the
N of Lys-132 (Fig. 3, bottom row, right).
Structural Differences between Heparin and 2,5DHPS-bound
FGF-1—There are obvious differences between the structure of
the protein complexed with either GA or 2,5DHPS and that
activated by heparin (45). First, there is a general relocation of
the lateral cationic chains that form the heparin binding site, an
elongated channel that is probably partially induced by the even
distribution of strong negative charges along the longitudinal
axis of heparin. This channel practically disappeared in the case
of the inhibitors, as those cationic side chains clustered around
a more punctually localized charge (Fig. 2, middle row). When
the structures of FGF-1 complexed to the inhibitor or heparin
were superimposed (Fig. 3, top row, right), there were small
FIGURE 3. Binding of GA, 2,5DHPS, heparin, and 5A2NMS to FGF-1. Top row, left, shown is a superimposed three-dimensional structure of the FGF-1
backbone bound to 2,5DHPS (cyan) and GA (white) at the inhibitor binding site represented in Fig. 2; right, shown is a stereoview of the superimposed
three-dimensional structure of the FGF-1 backbone bound to 2,5DHPS (cyan) and heparin (yellow) (45). For orientation purposes 2,5DHPS is represented at its
binding site as a stick model, with the carbon, oxygen, and sulfur atoms coloredwhite, red, and yellow, respectively. Representations were generated with the
Discovery Studio Visualizer program in the first case and with the PyMOL program in the latter. In both cases the backbones of the superimposed molecules
were reciprocally oriented to aminimal root mean square deviation with the program used to generate their representations. Displacement of the backbone
at the level of the 3/4 loop is not properly appreciated at the figure because the perspective of the drawing. Middle row, left, shown are superimposed
three-dimensional structures of the amide backbone of FGF-1 bound to 2,5DHPS (cyan), GA (white), and 5A2NMS (green). Middle row, right, shown are
superimposed three-dimensional structures of the amide backbone of FGF-1 bound to heparin (yellow) and incorporated into two different models of the
FGF-1FGFR2 complexes (orange, symmetric; red, asymmetric). The complex also includes heparin in the case of the asymmetric model (45, 51, 57). Superim-
posed molecules were reciprocally oriented to a minimal root mean square deviation and represented using PyMOL. Bottom row, shown is a network of
non-covalent interactions between FGF-1 and 2,5DHPS (left) and GA (right). The ligands and the protein are shown as stick-and-ballmodels, respectively, with
the atoms colored as above. Superimposed molecules were reciprocally oriented to a minimal root mean square deviation and represented using PyMOL.
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displacements of the loops connecting -strand 1 with 2 and
strand 11 with 12, which pertain to the inhibitor binding site
(-strand 10, the third secondary structure element of the bind-
ing site, did not show any appreciable displacement). As shown
in the same figure, alterations of regions unrelated to this site
(e.g. loops 2/3, 3/4, 4/5,  strand 8/9 hairpin) were also
observed,more dramatically in certain loops. It should be noted
that in the four molecules of the asymmetric unit where either
2,5DHPSorGAwere not detected, the backbone of the strand
8/9 hairpin adopted different positions intermediate to that of
inhibitor or heparin-bound FGF-1. Moreover, a general loss of
electron density in the side chains
was observed that did not permit
most of them to be traced. Conse-
quently, it seems that the  strand
8/9 hairpin is disordered in the
absence of ligands. A similar situa-
tion was observed when the struc-
ture of FGF-1 bound to 5A2NMS
was resolved (26).
According to the three-dimen-
sional structures currently available,
FGFs interact directly with the D2
and D3 immunoglobulin domains
of their FGFRs. In the case of FGF-1,
two different architectures of the
FGFFGFR complex have been pro-
posed, known as the symmetric
and asymmetric models (51, 57),
whereas only the symmetric one has
been described for FGF-2 (58).
Assembly of the asymmetric model
necessarily requires heparin to inte-
grate into the complex, which is not
the case of the symmetricmodel (51,
57, 58). In the case of the symmetric
model, studies carried out with
FGF-2 show that the incorporation
of heparin does not cause dramatic
changes in the interaction between
the growth factor and its receptor
(59). However, although the three-
dimensional structure of a symmet-
ric FGF-1FGFRheparin complex is
not yet available, if such a complex
exists, it seems reasonable that the
interactions between its polypep-
tide units would not be very differ-
ent to those in the absence of hepa-
rin, given the strong similarities
between the symmetric FGF-
1FGFR and FGF-2FGFR models
(60). The ensuing discussion will be
carried out on the basis of the inter-
action of FGF-1 with FGFR2, as to
date it constitutes the only complex
for which data are available for both
the symmetric and asymmetric
models (51, 57). In both models, the interaction of FGF-1 with
theD2 domain is the same. The tip of the strand 8/9 hairpin is
fundamental in this interaction of FGF-1 with the D2 domain,
as 6 of the 13 amino acids that interface with the receptor
belong to this region. As already mentioned, this region has a
different relative position with respect to the rest of the mole-
cule when FGF-1 is bound to heparin and to GA or 2,5DHPS.
Accommodating this displacement necessarily affects the side
chain of the neighboring residues, causing a clear distortion of
the whole interface (Fig. 4, top row). In the case of the D3
domain, the FGF-1 interfaces that recognize the receptor are
FIGURE 4. Surface defined by the amino acids of FGF-1 that interface with FGFR2, in the case of the
symmetric model of the complex and of the asymmetric model, when bound to heparin and 2,5DHPS,
respectively. Top row, the surface is defined by the amino acids in FGF-1 that interact with the D2 immuno-
globulin domain. These residues are the same in the asymmetric and symmetric three-dimensional structures
of the FGF-1FGFR2 complex (51, 57).A, FGF-1 bound to heparin is shown. B, FGF-1 bound to 2,5DHPS is shown.
In both cases the protein is oriented identically, as the backbone trace (yellow) shows. The following amino
acids of FGF-1 interact with the D2 immunoglobulin domain: Tyr-29 ( strand 1); Arg-49 ( strand 2); Arg-51
(loop  strands 2/3); Glu-101, Leu-103 ( strand 8); Asn-106, His-107 (loop  strands 8/9); Tyr-108, Asn-109 (
strand 9); Leu-147, Pro148; Leu-149, Pro-150 ( strand 12). Bottom row, shown is a three-dimensional represen-
tation of the surface defined by the whole set of amino acids of FGF-1 that interact with the D3 immunoglob-
ulin domain in the asymmetric and in the symmetric three-dimensional structures of the FGF-1FGFR2 com-
plex. C, FGF-1 bound to heparin is shown. D, FGF-1 bound to 2,5DHPS is shown. In both cases the protein is
identically oriented, as the backbone trace (yellow) shows. Circled residues are common to the interfaces of the
symmetric and the asymmetric models. The interface with the D3 domain includes the residues circled plus
those on top of them in the case of the asymmetric model and those to their left in the case of the symmetric
one. The following amino acids are specific to the interface with the D3 domain in the asymmetric model:
Leu-60, Arg-102, Leu-103, Glu-105, Asn-106, His-107, and Ile-112. Those specific to the symmetric model are:
Tyr-22, Lys-23, Pro-25, Lys-26, Leu-28, and Tyr-69. The following residues are common to the interface in both
models (circled): Ser-61, Ala-62, Glu-63, Ser-64, Val-65, Gly-67, Val-68, Ile-70, and Glu-101. Arrows point toward
the residuesmost displacedwhen FGF-1 binds 2,5DHPS instead of heparin. The figure was generated, and the
surfaces are colored according the electrostatic potential (red, negative; blue, positive) using Discovery Studio
Visualizer and its internal parameters.
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different in the symmetric and asymmetric models, although
they share a common region at the vertex of what is the approx-
imately a right angle defined in the FGF-1 surface by both inter-
faces when they are represented simultaneously (encircled in
Fig. 4, bottom row). The general rearrangement imposed by the
alteration of the heparin binding site when 2,5DHPS and GA
bind to FGF-1, in addition to the displacement of the  strand
8/9 hairpin, also affects the interfaces of FGF-1 with the FGFR
D3 domain in both the symmetric and asymmetric model
(Fig. 4).
Inhibition of OtherMembers of the FGF Family—The crystal-
lographic data clearly suggested that 2,5DHPS should also
inhibit FGF-2-induced mitogenesis, as the 2,5DHPS binding
site in FGF-1 is highly conserved in FGF-2 (see above), and they
both show a high affinity for strong anions (52–54). Indeed,
2,5DHPS inhibits FGF 2-driven mitogenesis with an I50 of 19.1
M (Fig. 1D). It should be pointed out that the rate of mitogen-
esis elicited by both FGF-1 and FGF-2 at inhibitory concentra-
tions of 2,5DHPS corresponds to that elicited by themitogen in
the absence of heparin (that in the case of FGF-1 is practically
unappreciable) (61). Thus, inhibition by 2,5DHPS cancels out
the effect of sulfated glycosaminoglycans on FGF-driven mito-
genesis (9, 62, 63). Given the homologies in primary structure, it
would not be totally unexpected if FGF-3, FGF-4, FGF-8,
FGF-9, FGF-16, and FGF-17 were also inhibited by 2,5DHPS
and GA, as there is substantial conservation in the binding site
between FGF-1 and each of these other family members,
although not as tight as with FGF-2.
Stability of 2,5DHPS in the Presence of FGF-1—GA and
2,5DHPS bind to a site in FGF with a particularly high specific
affinity for anions (Fig. 2). At the pH of the mitogenesis assays
(pH 7.5), the solutions of both compounds swiftly turned yel-
low, an effect that could be reversed by acidification to a pH of
5.5. Subsequently, the solutions slowly acquire a slight brown
color due to the appearance of a broad absorbance band reflect-
ing the spontaneous appearance of a heterogeneous assortment
of polyaromatic compounds due to quinone oxidation (Fig. 5).
At pH values above 9, the process was considerably faster, and
the solution became dark brown. Nevertheless the process
slows down rapidly and spontaneously unless the solution is
strongly buffered, as the formation of the brown pigment
causes a quick drop in pH. Evidently, quinone oxidation would
be accelerated considerably in a basic environment such as that
at the FGF site to which GA and 2,5DHPS bind, unless their
anionic form is stabilized by the opposing charges that sur-
round them. This would seem to be the case for 2,5DHPS
bound to FGF-1 as, in the presence of equimolar concentrations
of this protein, degradation products do not accumulate in the
2,5DHPS solution after 48 h at the pH and ionic strength of the
mitogenesis assays (Fig. 5). This would suggest that the ionized
hydroquinone of GA and 2,5DHPS actually substitutes for the
anions found at their binding site in the three-dimensional
structures of both FGF-1 and FGF-2, either free or complexed
to heparin (45, 51–54). Kinetic coupling between hydroqui-
none unprotonation and binding should make the later effect
quite cooperative.
Competition between 2,5DHPS and Heparin in Binding to
FGF-1 and FGF-2—The analysis of the three-dimensional struc-
tureofFGF-1boundto2,5DHPSsuggests that this inhibitorwould
compete with heparin for binding to FGF-1 and FGF-2. The per-
tinent studies confirmed these predictions.
Given the important structural similarities of the GAFGF-1
and 2,5DHPSFGF-1 complexes, studies were carried out with
2,5DHPS, the strongest of the two inhibitors. Competitive
binding of 2,5DHPS and heparin to FGF was tested by heparin
affinity chromatography. As expected, there was a decrease in
the protein retained as the heparin concentration in the FGF-1
solution injected onto the column increased (Fig. 6A). Likewise,
adding 2,5DHPS to the FGF solution produced an equivalent
effect to heparin, both with FGF-1 and FGF-2, albeit at higher
concentrations of the competitor in both cases (Fig. 6A). It
should be pointed out that in all cases the ionic strength of the
FGF solution in the presence of 2,5DHPS was considerably
lower than that required to elute the protein from a heparin
affinity chromatography column (12). Consequently, injection
of FGF-1 onto the column (which has less affinity for heparin
than FGF-2) in a solution containing 500 mM NaCl (a salt con-
centration that raised the conductivity of the solution to 30
millisiemens/cm and that was equivalent to that of the highest
2,5DHPS solutions used in the experiment) did not affect pro-
tein retention (data not shown). It should be also noted that the
2,5DHPS solution was prepared just before the mixture was to
be injected onto the column. This competition between
2,5DHPS andheparinwas then also tested inmitogenesis assays
at subsaturating concentrations of heparin (Fig. 6B, first against
eighth bars). The results show that 2,5DHPS decreased the rate
of mitogenesis to a level similar to that of quiescent cells (bar
FIGURE 5.Stabilizationof 2,5DHPS in solutionbyFGF-1.Absorbance spec-
tra are shown of 2,5DHPS (100 M) in the presence (2 and 4) and absence (1
and 3) of an equimolar concentration of FGF-1, recorded just after the prep-
aration of the solution (spectra 3 and 4) and 48 h later (spectra 1 and 2). Solu-
tions were at the pH (7.5) and ionic strength (20 mM sodium phosphate, 75
mMNaCl) of themitogenesis assay cultures. Approximately 10%of 2,5DHPS is
lost by oxidation during the 48 h of incubation, according to the 1H NMR
spectra of the initial and final solutions.mAU, milliabsorbance units.
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labeledMM), which could be compensated by an increase in the
heparin concentration in the assay.
2,5DHPS Competes with Heparin for Binding to FGFRs—The
FGF receptors share a highly conserved heparin binding site
that is essential for FGF-stimulated cell growth (64). Accord-
ingly, we explored whether 2,5DHPS interacts with FGFRs and
if this interaction interferes with FGF driven mitogenesis. A
series of experiments were carried out with FR1c-11 cells, a
heparin-less lymphoid cell line stably transfected with the full
three-Ig domainmurine FGF receptor 1 (splice variant IIIc (65–
67)). Pretreatment with 2,5DHPS caused an almost complete
inhibition of FGF-1-induced cell division, even after an exten-
sive washing of the cells (“Experimental Procedures” and Fig.
6C). However, this effect was overridden by increasing the con-
centration of heparin during the preincubation with 2,5DHPS.
It is obvious that a dual inhibitory target, the growth factor and
its receptor, constitutes a kinetic feature of FGF-driven inhibi-
tion of mitogenesis inhibition by 2,5-dihydroxyphenylic acids
that has to be taken into account. Moreover, given the highly
conserved heparin binding sites in the four FGFRs, it would not
be totally unexpected if all of them were capable of binding
these acids, which would obviously considerably widen the
spectrum of FGF-driven processes that these 2,5-dihydroxy-
phenyl derivatives can inhibit (64).
In vitro studies were carried out to further assess the compe-
tition between heparin and 2,5DHPS for binding to FGFRs.
Thus, the complete extracellular domain of the IIIc isoform of
receptor 2 (exdFGFR2IIIc) was synthesized and purified (upper
inset of Fig. 7A). This isoform displays equivalent affinity for
FGF-1 and FGF-2 (the FGFR variant present in FR1c-11 cells
has higher affinity for FGF-1 than for FGF-2) (66). Evaluation of
the secondary structure of exdFGFR2IIIc from its UVCD spec-
trum (Fig. 7A) using an unsupervised learning neural network
yielded a -sheet content of the polypeptide, in agreement with
that computed from the crystallographic structures (41%;
maximum error, 0.087) (51, 57, 60, 68). The low light scattering
of the UV spectra at0.5 mg/ml (Fig. 7A, lower inset) and the
affinity for heparin (Fig. 6D) both also argue in favor of the
correct folding of the synthesized exdFGFR2IIIc (64). More-
over, NMR spectroscopy showed that the exdFGFR2IIIc syn-
thesized recognized FGF-1. The 1H,15NHSQC spectrum of the
15N-labeled FGF-1 backbone was determined in the presence
FIGURE 6. Competition between heparin and 2,5DHPS. A, shown is the
amount of FGF retained on a 1-ml HiTrapTM heparin HP column (GE Health-
care)when co-injectedwith either heparin (f) or 2,5DHPS (Œ,F). The amount
of protein retained is represented by the height of the peak eluted with a
5-min linear gradient of 300 to 1.5 M NaCl in the chromatography buffer after
post-injection column re-equilibration (20 mM sodium phosphate, 300 mM
NaCl, pH 7.2). The flow rate was 1 ml/min. The protein (13 M in 250 l; f, Œ,
FGF-1; F, FGF-2) was co-injected in the presence of different concentrations
of the competitor, as plotted in the graph. mAU, milliabsorbance units;
B, shown is reversion of the inhibition of the mitogenic activity of FGF-1 by
2,5DHPS at increasing heparin concentrations. The mitogenesis assay was
carried out as described under “Experimental Procedures” using murine
Balb/c 3T3 fibroblasts. C, FGF-1-driven mitogenesis of FR1c-11 cells preincu-
bated as indicated in the figure and under “Experimental Procedures”
(, equivalent levels of mitogenesis were observed when 1 g/ml of heparin
was included in the pretreatment). D, shown is the amount of exdFGFR2IIIc
retained in a HiTrapTM Heparin HP column (GE Healthcare) when co-injected
with increasing concentrations of heparin (Œ) or 2,5DHPS (F) using the chro-
matographic conditions described above.
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and absence of 50 M exdFGFR2IIIc (Fig. 7B). The two-dimen-
sional distribution of cross-peaks, already fully characterized,
represented a fingerprint of the protein (35). The intensity of
the signals in these spectra is inversely related to the size of the
protein, as the line width of the signal is inversely proportional
to the transverse relaxation time (T2), which decreases as the
efficiency of relaxation increases with the size of the molecule.
This feature can be used tomonitor the formation of complexes
between polypeptides. As the lower panel shows, there was a
significant line broadening of most of the FGF-1 signals upon
the addition of exdFGFR2IIIc, which causes many of them to
remain hidden below the spectral noise. The framed cross-
peaks corresponded to groups belonging to highly flexible
regions of the protein, whose transverse relaxation time
remained largely independent of the overall size of the polypep-
tide (35). Because the position and intensity of these cross-
peaks remained practically the same in the upper and lower
panels of the figure, the overall decrease in intensity of the rest
of the signals cannot be attributed to 15N-labeled FGF-1 com-
ing out of solution upon the addition of exdFGFR2IIIc.
STD NMR experiments (Fig. 7C) clearly demonstrated that
exdFGFR2IIIc interacts with 2,5DHPS, as predicted from the
experiments with FR1c-11 cells. Indeed, the characteristic sig-
nals of 2,5DHPS were clearly visible in the middle record, indi-
cating that the excitation of the protein was transferred to the
inhibitor, and consequently, that it binds to exdFGFR2IIIc (69).
The possibility that both heparin and 2,5DHPS compete for
binding to FGFRs was explored using the same approach
employed with FGF-1 and FGF-2 (Fig. 6A). Accordingly,
2,5DHPS clearly interfered with the binding of the external
domain of the receptor to heparin (Fig. 6D), an effect that again
could not be emulated bymerely raising the conductivity of the
buffer with NaCl to that of the highest 2,5DHPS solution used
in the experiment (25 millisiemens/cm).
To determine whether 2,5DHPS could interfere with the
binding of FGF to exdFGFR2IIIc, a hybrid C-LYT/aFGF
polypeptide was used (36). The mitogenic activity and heparin
FIGURE 7. Characterization of recombinant exdFGFR2IIIc. A, circular
dichroism spectra in the far-UV region of exdFGFR2IIIc are shown. Closed cir-
cles represent the spectrum reconstructed on the basis of the percentage of
the secondary structure components of exdFGFR2IIIc obtained by deconvo-
lution of the experimental spectrum (DICHROWEB server (68, 90).Upper inset,
Coomassie Brilliant Blue-stained SDS/polyacrylamide electrophoresis gel
(15%) (50) of recombinant exdFGFR2IIIc after purification and refolding (the
horizontal lines to the right indicate the position ofmolecularmassmarkers of
250, 75, 50, 37, and 25 kDa). Lower insert, UV spectra (0.5 mg/ml; 20 mM
Hepes, 150 mM NaCl (pH 7.5)) of exdFGFR2IIIc before (dotted line) and after
refolding are shown. AU, absorbance units. B, shown is a characteristic 1H,15N
HSQC spectrum of the backbone of 15N-labeled FGF-1 (150 M in 20 mM
sodium phosphate (pH 7.2), 300 mM NaCl) in the presence (lower panel) and
absence (upper panel) of 50M exdFGFR2IIIc. Framed 1H,15N cross-peaks cor-
respond to Gln-54 and Gln-91 N and His-138 N (1), Asp-154 N (2), and
Lys-23 andLys-24N (3).C, shown is an STD spectrumof a solutionof 2,5DHPS
and exdFGFR2IIIc in 20 mM sodium phosphate, 150 mM NaCl (pH 7.2) at a
molar ratio of 1 to 0.05 (middle spectrum). The top record is a 1HNMR spectrum
of the aromatic region of a 1 mM solution of 2,5DHPS in the same buffer. The
bottom trace is a STD spectrum equivalent to that of themiddle trace, except
that the protein was omitted. Circular dichroism spectra in the far UV region
were obtained using a Jasco 710 spectropolarimeter at 20 °C in a 1-mm path
length cuvette. Theprotein (0.13mg/ml)was in50mMsodiumphosphate (pH
7.0), and the spectra were averaged by accumulating four scans. A four-scan
averaged spectrum of the buffer was routinely subtracted from the protein
spectra.
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affinity of this polypeptidewas similar to that of FGF-1,whereas
through a combination of cation- and hydrophobic interac-
tions, it also binds strongly to choline analogues, like the anion-
exchange group of common chromatography solid phases
(diethylaminoethyl- and trimethylammonium-) (36, 70). As
hydrophobic interactions predominate in the binding of the
C-LYTmoiety to these choline analogues, once C-LYT/aFGF is
loaded onto such columns, it can only be eluted in the presence
of either choline or its analogues in
the chromatography buffer but not
by raising the ionic strength (36, 70,
71). Thus, C-LYT/aFGF enables
common anion exchange columns
to be converted into FGF affinity
columns from which FGF com-
plexes can be eluted with choline.
Accordingly, C-LYT/aFGF was
eluted from the chromatography
column when the choline concen-
tration in the buffer was raised to
150 mM (Fig. 8A), whereas when
exdFGFRIIIc was applied, the pro-
tein appeared in the flow-through,
and nothing was eluted by choline
under the same conditions (Fig. 8B).
However, when this protein was
injected in the presence of equimo-
lar amounts of C-LYT/aFGF, it was
retained, and both polypeptides
were eluted together in a single peak
(Fig. 8C, a) when the elution buffer
contained 150mM choline (see elec-
trophoretogramof this fraction, Fig.
8F, lane a). When 1 ml of a 100 mM
solution of 2,5DHPS (prepared just
before it was applied to the column
in Hepes 20 mM, adjusted to the
same pH (pH 7.5) and conductivity
(26 millisiemens/cm) as the chro-
matography buffer) was injected
before the choline elution step,
C-LYT/aFGF alone was detected in
this last eluted fraction (peak c of
Fig. 8D and Fig. 8F, lane c of the
electrophoretogram). SDS-PAGE of
the washout after 2,5DHPS injec-
tion confirmed that exdFGFR2IIIc
was eluted in this fraction (Fig. 8D,
peak b and Fig. 8F, lane b of the elec-
trophoretogram). Similar results
were obtained when the protein
mixture injected onto the col-
umn contained an equimolar
amount of heparin. The incorpo-
ration of heparin to the C-LYT/
aFGFexdFGFR2IIIc complex under
these chromatographic conditions
was evident by the higher ionic
strength required to dissociate exdFGFR2IIIc in the presence of
heparin (Fig. 8E). Such a moderate effect was predicted by the
structural crystallography data given theminimal interaction of
heparin with the receptor and also by the cell biology experi-
ments (51, 57–59, 72). As C-LYT/aFGF cannot be eluted from
the column by raising the ionic strength of the buffer, the chro-
matographic effect shown in Fig. 8E exclusively reflects the dis-
sociation of the C-LYT/aFGFexdFGFR2IIIc complex (36, 70).
FIGURE 8. Chromatography of C-LYT/aFGFexdFGFR2IIIc complexes. The protein (3.2 nmol in each case)
was injected in 250 l of the chromatography buffer at the arrows labeled INJ. The buffer contained 150 mM
choline from the mark (arrow labeled CHL) to the end of the chromatogram. A, C-LYT/aFGF is shown.
B, exdFGFRIIIc is shown. C, an equimolar mixture of C-LYT/aFGF and exdFGFRIIIc is shown. D, an equimolar
mixture of C-LYT/aFGF and exdFGFRIIIc is shown as in C, except that 1 ml of a 100 mM 2,5DHPS was injected
onto the column (arrow) before raising the choline concentration of the buffer to 150mM (in C andD, the peak
eluted with choline has a long tail only partially shown in the figure). E, shown is the chromatography of an
equimolar mixture (3.5 nmol) of C-LYT/aFGF and exdFGFRIIIc (containing 5mM 3-kDa heparin, in the case of
the dashed line) using a NaCl gradient (dotted line; except for this NaCl gradient, the other chromatographic
conditions are those used in the remainder of the figure).mAU, milliabsorbance units. F, shown is Coomassie
Brilliant Blue-stained SDS/PAGE (15%) of the fractions a, b, and c of the chromatograms C andD. The horizontal
lines to the left indicate the migration of C-LYT/aFGF (30.8 kDa) and exdFGFRIIIc (38.7 kDa). Chromatography
was carried out on 1-ml HiTrapTM DEAE FF columns (GE Healthcare) at a flow rate of 2 ml/min and a pH of 7.5
(Hepes 20mM, 300mMNaCl), conditions chosen to avoid any appreciable ionic interaction of FGF-1 (pI 7.9) and
exdFGFR2IIIc (pI 5.8), respectively, with the solid phase of the column.
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2,5DHPS Inhibition of Cell Migration—FGF signaling may
affect important disease-associated processes other than
growth. Given the fundamental importance of cell migration in
the development ofmany important pathologies in which FGFs
seem involved, whether 2,5DHPS could inhibit FGF-induced
cell migration was evaluated (20–25). The capacity of FGF-2 to
induce cell migration of bovine aortic endothelial cells from the
edge of a denuded area in a confluent monolayer was demon-
strated by Sato and Rifkin (73). This process, characterized by
the disruption of the confluent monolayer structure of the cul-
ture, the appearance of cells with extended filopodia, and the
invasion of the denuded plate area, could also be observedwhen
Balb/c 3T3 fibroblasts cultures were exposed to either FGF-1 or
FGF-2 (Fig. 9A). The figure also shows that, in effect, 2,5DHPS
clearly inhibited FGF-1- and FGF-2-induced cell migration (I50
100 M). Complete inhibition was achieved by 2,5DHPS at
concentrations close to those that produced amaximal effect in
the mitogenesis assays (200 M).
2,5DHPS Inhibits Angiogenesis and Glioma Growth in Vivo—
A more holistic preliminary approach to study the effects of
2,5DHPS in vivo was undertaken using two animal models of
pathological angiogenesis and tumor growth.
Abnormal unrestrained angiogenesis can be evoked in vivo in
rats by implanting collagen sponges soaked in inducers of
angiogenesis subcutaneously (74), a model we have used
repeatedly to evaluate FGF-induced angiogenesis (26, 75). The
model was also used to evaluate the potential antiangiogenic
activity of 2,5DHPS using gelatin sponges to permit a more
precise histological evaluation. When removed 7 days after
their implantation in untreated rats, sponges embedded with
FGF-1 had an intensely bloody appearance (left sponge, Fig. 9B),
contrasting with the sponges removed from rats to which
2,5DHPS was administered and that displayed no macroscopic
evidence of angiogenesis (right sponge). Invasion of the sponge
by tortuous blood vessels similar to those observed in tumor
angiogenesis could be observed in amplified images after man-
ually modifying the color hue to better appreciate the invading
vessels. 2,5DHPS was administered orally in the cases shown in
the figure, although the treatment was equally effective when
the inhibitor was administered intraperitoneally and when
FGF-2 was employed instead of FGF-1.
Prominent vascularization is an outstanding feature of glio-
mas, a tumor type that accounts for60% of primary intracra-
nial neoplasms, and this is considered a key characteristic in
their malignancy (76). FGF-1 and FGF-2 are abundant in most
glioblastomas, and although the former is associated to astro-
cytes, the latter is associated with the matrix surrounding pro-
liferating blood vessels (77). In addition, they seem to constitute
autocrine factors essential for the survival and proliferation ofFIGURE 9. Inhibition by 2,5DHPS of FGF-induced cell migration and ofuncontrolled growth in vivo. A, top panel, the effect of different doses of
2,5DHPS on the migratory phenotype induced by either FGF-1 or FGF-2 in
woundedconfluent culturesof fibroblasts Balb/c 3T3 cells is shown.A,bottom
panel, shown are representative photographs of the experiment (2,5DHPS,
200 M). The black arrow points to a cell with a long filopodium, a character-
istic of migrating cells colonizing the denuded area. Data are plotted as the
meanS.E. of thenumberofmigrating cells invading thewoundmade in the
culture. ***, p	 0.001 versus column 1; †††, p	 0.001 versus columns 3 and 6
for the wells treated with FGF-1 and FGF-2, respectively, as assessed by one-
factor analysis of variance followed by the Student-Newmann-Keuls test.
B, left plot, shown is the effect of orally administered 2,5DHPS on blood vessel
invasion of gelatin sponges soaked in FGF-1 and implanted subcutaneously
in rats. B, right panel, shown are representative photographs of the
experiment. The image in the second row is an amplification of the boxed area
in the image abovewith the color huemanuallymodified to better appreciate
of the blood vessels. Data are plotted as themean S.E. ***, p	 0.001 versus
vehicle by unpaired t test. C, left panel, shown are the effects of 2,5DHPS on
the progress of subcutaneously implanted rat gliomas. C, right panel, shown
are representative photographs of tumors with a size representing approxi-
mately themean of the plot at the left. The data are expressed as themean
S.E. of the volume of excised gliomas at the end of the intraperitoneal treat-
ment. *, p	 0.05 versus vehicle by unpaired t test.
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themalignant gliomal cells (78, 79). Combining anti-angiogenic
and anti-mitotic agents have been proposed to treat gliomas
because the efficacy of antiangiogenic treatments alone
remains uncertain (80). The FGF inhibitors described heremay
fulfill both therapeutic goals. Consequently, gliomas seemed to
be an appropriate pathological model to determine whether
these compounds may be suitable for pharmacologically use in
vivo. To this end, C6 rat glioma cells grown in vitro were
implanted subcutaneously into 12 rats in accordance with a
well known heterotopic model of glioma (41). Five days after
implantation,when the tumors clearly protrude throughout the
skin, the rats were randomly divided into two groups that
received a daily intraperitoneal injection of either the vehicle
alone or 2,5DHPS. The tumorswere surgically removed 10 days
after the onset of the treatment, and their volume was deter-
mined. In Fig. 9C, two tumors with the average size of those
extirpated from the treated anduntreated animals, respectively,
clearly show that 2,5DHPS administration significantly
impaired the development of the tumor. Moreover, the
decrease in blood irrigation to the tumors extracted from the
2,5DHPS-treated animals was clearly evident from their color.
DISCUSSION
FGFs seem to be involved in a wide assortment of patholo-
gies, and they promote the resistance of tumors to chemother-
apy drugs and radiation. Considerable attention has been paid
to their involvement in anomalous angiogenesis, as it has grad-
ually become clear that uncontrolled angiogenesis causes or is
necessary for the progress of many diseases, including cancer
(81).Hence, the pharmacological inhibition of FGFsmight be of
considerable therapeutic interest.
The critical nature of the relative positions of the hydroxyl
groups in the aromatic ring of the new family of FGF inhibitors
described here could not have been foreseen in earlier studies.
Furthermore, the orientation toward the solvent of the acidic
group in GA and 2,5DHPS bound to FGF-1 was quite unex-
pected from both the three-dimensional structure of 5A2NMS
bound to FGF-1, the inhibitor that led us to single out GA as a
potential FGF inhibitor (26), and the affinity for strong anions
of the groove at the FGF surface where GA and 2,5DHPS dock
(45, 51–54). The high affinity for strong anions in this region of
FGF clearly suggests that the hydroquinone moiety of both GA
and 2,5DHPS fulfills this role in binding to FGF rather than
acting as a hydrophobic group and is more suitable to that pur-
pose than the smaller acidic groups of the inhibitors.
The hydroquinone ring of 2,5DHPS slowly oxidizes at the
physiological pH of the mitogenesis assays, although it is stabi-
lized in the presence of FGF. It would seem reasonable to
assume that the hydroquinone group should remain partially
unprotonated under such pH conditions, which when added to
the negative charge of its acidic group, should direct 2,5DHPS
toward its FGFbinding site.Once positioned in this highly basic
region, the hydroquinone ringmust become fully unprotonated
and acquire a markedly anionic character, which should con-
tribute decisively to displacing the acidic group toward the sol-
vent. Encapsulation of the benzene ring as a quinone-like struc-
ture inside this highly cationic shell seems to be sufficient to
account for the oxidation shielding observed under these con-
ditions. This model could reasonably be extended to the other
2,5-dihydroxyphenylic inhibitors described in this study. The
ortho and meta conformations are probably much less appro-
priate than the para isomer for the dihydroxyphenyl ring to
acquire such strong anionic character, which may account for
the striking inactivity of the rest of the GA isomers as FGF
inhibitors. The differences in the docking of GA and 2,5DHPS
at their FGF binding sites were unanticipated. It seems plausi-
ble that the cloud of  electrons of the aromatic ring loses the
characteristic donut-shape conformation required for canoni-
cal -stacking that is established for 2,5DHPS, due to the close
proximity of the resonant carboxylic group in GA (56).
Although initially conceived as a FGF trap and protector,
sulfated glycosaminoglycans were later shown to participate in
FGFR binding and activation (82). Accordingly, a quite
straightforward model can be proposed to explain the inhibi-
tory effects of the dihydroxyphenyl derivatives described here
based on the hindrance of heparin interaction with FGFs and
FGFRs. However, the crystallographic data and results pub-
lished elsewhere (26) might lead us to envisage a more sophis-
ticated scenario.
Free FGF-1 is a quite flexible polypeptide (83), a feature fur-
ther substantiated by the crystallographic data reported here
and elsewhere (26). However, upon binding to heparin and
other functional analogues of heparin, this dynamic free-
energy conformational landscape, with shallow transition
barriers and minor populated energy wells, clearly alters, as
the apoFGF-1 conformation most appropriate for binding to
these ligands accumulates in the solution (45, 83). This also
seems to be the case when apoFGF-1 faces 5A2NMS and the
family of 2,5-dihydroxyphenylic inhibitors described here
(26).
The backbone trace of FGF-1 bound to heparin in solution
(45) closely superimposes onto those of this polypeptide incor-
porated into either the asymmetric (containing heparin) or
symmetric FGF-1FGFR2 complexes (Fig. 3 middle row, right)
(45, 51, 57). This tight match suggests that the binding of
heparinFGF-1 to FGFRs predominantly occurs by a lock-and-
key rather than by an induced fitting mechanism (in the
absence of the activating ligand, induced fitting should pre-
dominate, with the subsequent entropic cost and the well doc-
umented requirement of higher growth factor concentrations
for activity). Differences in the conformations that preferen-
tially accumulate in the presence of heparin and the inhibitors
(Fig. 3) would necessarily have dramatic consequences on
receptor binding in a predominant lock-and-key kinetic land-
scape of receptor recognition. Accordingly, inhibition of FGF
by 5A2NMS and the family of 2,5-dihydroxyphenylic inhibitors
described here is probably caused by the accumulation of the
protein in a conformation incapable of fitting on the FGFR
interface in addition to the displacement of heparin from the
membrane signaling complex. It is obvious that further
research is required to ascertain whether this dual inhibitory
system also acts on other members of the FGF family.
Both the activators (heparin/heparin sulfate) and the inhibi-
tors referred to in this report have a common chemical feature,
that of being strong anions. Nevertheless, both groups clearly
differ in terms of plasticity; the activators are flexible, whereas
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the inhibitors are predominantly stiff. This difference may be
decisive in themechanisms sustaining their binding to FGFs, as
in the first case, the ligand easily adapts to the binding site, but
in the second, it is the binding site that has to adapt to the
ligand. This would be feasible for a flexible protein that would
easily sample within its free energy conformational landscape
for the most appropriated conformation for efficient ligand-
binding interaction. The discrete nature of this well landscape
probably explains why sorts of chemically distinct inhibitors
like 5A2NMSand 2,5-dihydroxyphenylic acids induce the same
protein conformation, whereas they also show different inhib-
itory efficiencies at the same time. Methylation and point-di-
rectedmutagenesis of Lys-132 have already highlighted the rel-
evance for FGF-1 activity of maintaining the integrity of the
architectural conformation of the site where 5A2NMS and the
family of 2,5-dihydroxyphenylic inhibitors described in this
study bind (8, 55). The adaptation necessary to bind these stiff
inhibitorsmay constitute anotherway of altering such architec-
ture. Finally, the existence of a well defined ligand-inducible
inhibited state of FGF-1 suggests that physiological ligandsmay
also exist that are responsible for such allosteric inhibition. The
results reported here obviously point toward HGA, although
any other compounds of similar chemical nature that may exist
in the organism should also be considered. By bearing in mind
that moderate levels of HGA may constitute a defense against
pathologies caused by the uncontrolled synthesis and cell
matrix release of FGFs, perhaps we could better understand the
prevalence of the recessive genetic disease alkaptonuria. On the
other hand, the inhibition of FGFs should probably be taken
into account when explaining the symptomatology of this
pathology.
FGF-1 and FGF-2were the first two pure polypeptides shown
to promote angiogenesis (84, 85), although there are currently
more than a dozen factors that promote angiogenesis and that
target the different cell types involved in vessel formation, most
of them identified in tumor proliferation studies (86, 87). The
formation of blood vessels requires a synergy betweenFGFs and
vascular endothelial cell growth factors (VEGFs), probably the
only ones that directly promote the proliferation of endothelial
cells (86). Thus, it is not surprising that increased expression of
FGFs and VEGFs is observed in many vascularized tumors
when compared with their normal tissue counterparts. Conse-
quently, inhibiting the mitogenic activity of FGF could be a
potential target for the development of antiangiogenic thera-
pies. Perhaps such an approach might serve as an alternative to
VEGF inhibitionworthy of exploration once cell biology studies
have presented data clearly substantiatingmuch emerging clin-
ical evidence that VEGF inhibition is not successful as a long
term anti-tumor therapy (88).
GA and 2,5DHPS seem to be very convenient compounds
as they can be taken orally and they are very safe. Adminis-
tering appropriate doses of a physiological metabolite, such
as HGA, might also be considered. In addition to being a
catabolite of aspirin, GA is present in extracts of gentian
roots that have been used for centuries as anti-inflammatory
agents and in bitter spirits. Moreover, GA accumulates in the
organism of subjects on vegetarian diets. 2,5DHPS is the
active principle of Doxium, a drug that is scarcely used and
that was employed for many years without any known side
effects as a vasculotropic agent, an effect apparently opposed
to that reported here. Indeed, our data might also help to
explain some of the therapeutic effects of aspirin, salicylate,
and vegetarian diets.
The 2,5-dihydroxyphenylic acids described here define a new
class of FGF inhibitors, and they constitute new leads to search
for drugs to treat diseases caused by uncontrolled synthesis/
release of FGFs. As their action could be based on an already
existing physiologicalmechanismof FGF inhibition, theymight
be expected to cause fewer problems than those produced by
antiangiogenic drugs that target VEGF activity (88).
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 1
SUPPLEMENTAL MATERIAL 
 
 
 
Figure S1. Expression of the extracellular domain (residues 25-361) of the receptor 
2 isoform IIIc (exdFGFR2IIIc). The expression cassette was constructed by the 
polymerase chain reaction (PCR) using pTK14 as the template (1) and ProteoExpert 
(Biomax Informatics AG) proposed modifications for optimal expression of the protein 
in E. coli. The cassette includes, the T7 promoter of phage RNA-polymerase (cyan), 
exdFGFR2IIIc with a His-tag fused to its C-terminus and optimized for Ni2+-chelating 
solid phase chromatography, and a 3’ UTR optimized for protein expression in which a 
T7 phage RNA-polymerase terminator is included (cyan). Initiating and terminating 
codons are in red characters.  
 
 
 
 2
 
 
 
Figure S2. Effect of the whole set of GA isomers on the FGF-1 induced mitogenesis 
of Balb/C 3T3 fibroblasts cultured in vitro. The isomers tested in each assay appear as 
an inset of the corresponding plot. Empty symbols represent the cell proliferation in 
unstimulated cultures, in the presence and absence of the corresponding isomer at the 
concentration indicated. The compounds do not seem to have any appreciable effect on 
the cell viability in quiescent cultures. 
 3
 
 
Figure S3. Stereoviews of the three-dimensional structure of the FGF-1:heparin 
complex at the 2,5DHPS and GA binding site (heparin shown as stick-and-ball model, 
with carbon, nitrogen, oxygen, and sulfur atoms colored white, blue, red, and yellow, 
respectively). The Van der Waals volume of the protein was generated with PyMOL 
(DeLano Scientific LLC) with the atoms colored as above. IDS-3, O2-sulfo-glucuronic 
acid at position 3 (from the reducing end). SGN-4, N,O6-disulfo-glucosamine at 
position 4.  
 
 
 
Figure S4. Three-dimensional representation of the region of the heparin binding-
site to which 2,5DHPS and GA dock in crystals obtained in the absence of ligands. The 
graphical representation corresponds to FGF-1 (A) showing a phosphate anion at the 
docking site (2,3). The walls of the groove at which the phosphate anion, 2,5DHPS and 
GA bind is made up of the Asn 32, Leu 125, Lys 126, Lys 127, Lys 132, Lys 142, Gln 
141, and Ala 143 residues. When the amide backbones of the FGF-1 and FGF-2 three-
dimensional structures are superimposed, these amino acids align with residues: Asn 36, 
Leu 127, Lys 128, Arg 129, Lys 134, Lys 144, Gln 143 and Ala 145 of FGF-2 (B), 
which also create a groove at which a selenate anion docks at an equivalent relative 
position to that of the phosphate in the case of FGF1 (4). The electrostatic potential of 
the protein surface, is mapped in blue (positive) and red (negative) and it was generated 
with the Discovery Studio Visualizer program (2.0.1.7347; Accelrys Software Inc.) 
using its internal calculation parameters. 
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